Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Oramed Pharmaceuticals (ORMP) EPS (Weighted Average and Diluted) (2021 - 2026)

Oramed Pharmaceuticals filings provide 5 years of EPS (Weighted Average and Diluted) readings, the most recent being $0.24 for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) rose 192.31% to $0.24 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.49 through Dec 2025, up 410.42% year-over-year, with the annual reading at $1.5 for FY2025, 412.5% up from the prior year.
  • EPS (Weighted Average and Diluted) hit $0.24 in Q4 2025 for Oramed Pharmaceuticals, down from $1.13 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $1.13 in Q3 2025 and bottomed at -$0.78 in Q3 2021.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.04, with a median of -$0.08 recorded in 2023.
  • The largest annual shift saw EPS (Weighted Average and Diluted) surged 833.33% in 2024 before it crashed 575.0% in 2025.
  • Oramed Pharmaceuticals' EPS (Weighted Average and Diluted) stood at -$0.78 in 2021, then skyrocketed by 61.7% to -$0.3 in 2022, then skyrocketed by 210.3% to $0.33 in 2023, then tumbled by 178.79% to -$0.26 in 2024, then skyrocketed by 192.31% to $0.24 in 2025.
  • Per Business Quant, the three most recent readings for ORMP's EPS (Weighted Average and Diluted) are $0.24 (Q4 2025), $1.13 (Q3 2025), and $0.31 (Q2 2025).